Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

McGill University

$27,000.00

Comparative DNA Methylation of HPV16 vs. Other High-Risk HPV Genotypes in Oropharyngeal Cancer (OPC)

FY 2025-26

Summary
Head and neck cancers, namely oropharyngeal cancers (OPC), represent a growing public health burden in Canada. A large proportion of OPC cases are driven by high-risk human papillomavirus (HPV) infections, most notably HPV16. While HPV16 is the predominant genotype, other high-risk genotypes are also implicated and emerging evidence suggests that patient prognosis varies according to HPV genotype yet the biological mechanisms underlying these differences remain unresolved. Epigenetic regulation, particularly DNA methylation, is believed to play a key role in HPV-associated tumorigenesis yet genotype-specific epigenomic alterations remain poorly characterized. This project aims to characterize and compare the genome-wide DNA methylation profiles of OPC tumours driven by HPV16 versus other high-risk HPV genotypes. It is hypothesized that HPV16-positive tumours exhibit distinct epigenetic signatures that enhance viral persistence, immune evasion and oncogenic activity, contributing to their unique clinical behaviour and prognosis. Tumour samples from 100 OPC patients will be stratified by HPV genotype and HPV status will be confirmed by real-time PCR prior to genome-wide DNA methylation profiling. Differentially methylated regions will be identified using established bioinformatic pipelines and correlated with key clinical outcomes such as overall survival, disease recurrence, and immune cell infiltration. Subgroup analyses based on tumour stage, smoking status and immune marker expression will be conducted. By integrating epigenomic and clinical data, this study aims to uncover genotype-specific epigenetic drivers of OPC and identify novel prognostic biomarkers with potential clinical utility for risk stratification and therapeutic decision-making in HPV-associated OPC.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572958
Name
Tamashekan Darya
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Comparative DNA Methylation of HPV16 vs. Other High-Risk HPV Genotypes in Oropharyngeal Cancer (OPC)
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Dna Methylation; Epigenetics; Head And Neck Squamous Cell Carcinoma (Hnscc); Hpv16; Hpv16-Positive Tumours; Human Papillomavirus (Hpv); Oropharyngeal Cancer (Opc); Prognosis; Tumour Biology; Tumour Genetics
Abstract
Head and neck cancers, namely oropharyngeal cancers (OPC), represent a growing public health burden in Canada. A large proportion of OPC cases are driven by high-risk human papillomavirus (HPV) infections, most notably HPV16. While HPV16 is the predominant genotype, other high-risk genotypes are also implicated and emerging evidence suggests that patient prognosis varies according to HPV genotype yet the biological mechanisms underlying these differences remain unresolved. Epigenetic regulation, particularly DNA methylation, is believed to play a key role in HPV-associated tumorigenesis yet genotype-specific epigenomic alterations remain poorly characterized. This project aims to characterize and compare the genome-wide DNA methylation profiles of OPC tumours driven by HPV16 versus other high-risk HPV genotypes. It is hypothesized that HPV16-positive tumours exhibit distinct epigenetic signatures that enhance viral persistence, immune evasion and oncogenic activity, contributing to their unique clinical behaviour and prognosis. Tumour samples from 100 OPC patients will be stratified by HPV genotype and HPV status will be confirmed by real-time PCR prior to genome-wide DNA methylation profiling. Differentially methylated regions will be identified using established bioinformatic pipelines and correlated with key clinical outcomes such as overall survival, disease recurrence, and immune cell infiltration. Subgroup analyses based on tumour stage, smoking status and immune marker expression will be conducted. By integrating epigenomic and clinical data, this study aims to uncover genotype-specific epigenetic drivers of OPC and identify novel prognostic biomarkers with potential clinical utility for risk stratification and therapeutic decision-making in HPV-associated OPC.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tamashekan, Darya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~